Stock comparison
AbbVie Inc. is 50.9x more valuable than Nuvalent, Inc. by market capitalization ($440.14 B vs $8.64 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
ABBV is larger
AbbVie Inc. is 50.9x more valuable than Nuvalent, Inc. by market capitalization ($440.14 B vs $8.64 B).
Market value leader
ABBV
AbbVie Inc. is 50.9x more valuable than Nuvalent, Inc. by market capitalization ($440.14 B vs $8.64 B).
Profit leader
ABBV
NUVL: -$425.40M vs ABBV: $4.23B.
| Metric | NUVL | ABBV |
|---|---|---|
| Market cap | $8.64 B | $440.14 B |
| US-listed rank | #1045 | #25 |
| Revenue (latest FY) | - | $61.16B |
| Net income (latest FY) | -$425.40M | $4.23B |
| Net margin | - | 6.9% |
| P/E (trailing FY) | - | 104.2x |
| SEC filings | 529 | 1,008 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
AbbVie Inc. is 50.9x more valuable than Nuvalent, Inc. by market capitalization ($440.14 B vs $8.64 B).
Full pages: Nuvalent, Inc. and AbbVie Inc., or browse the full rankings.